Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 1998, p. 3113-3116, Vol. 42, No. 12
Laboratoire de Recherche Moléculaire
sur les Antibiotiques, UFR Broussais-Hôtel Dieu and UFR
Pitié-Salpêtrière, Université Paris
VI,1 and
Laboratoire de
Bactériologie, Hôpital Saint-Louis, Université
Paris VII,2 Paris, France
Received 25 February 1998/Returned for modification 3 June
1998/Accepted 20 September 1998
A clinical isolate of Pseudomonas aeruginosa, PAe191,
was found to be highly resistant to all anti-Pseudomonas
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Novel OXA-10-Derived Extended-Spectrum
-Lactamases Selected In Vivo or In Vitro

-lactam antibiotics (except imipenem) and resistant also to
aminoglycosides. It produced a
-lactamase (with an apparent pI of
7.6) which was not inhibited by clavulanic acid. Cloning and
characterization of the
-lactamase gene showed that it coded
for a novel extended-spectrum OXA-10 variant, called OXA-19, which
differed from OXA-10 by nine amino acids and from OXA-13 by two, i.e.,
Asn in position 73 (Asn73) instead of Ser and Asp157 instead of Gly.
Asparagine in position 157 is implicated in resistance to ceftazidime,
while the amino acid in position 73, in this variant, seems to
condition the level of resistance to penicillins. The oxa19
gene was found to be inserted, in a typical integron structure,
immediately downstream from an aac(6')-Ib gene coding for an
aminoglycoside acetyltransferase variant, which was called
AAC(6')-Ib9.
*
Corresponding author. Mailing address: L.R.M.A.,
Université Paris VI, 15, rue de l'Ecole de Médecine, 75270 Paris Cedex 06, France. Phone: 33-1-42 34 68.65. Fax: 33-1-43.25.68.12. E-mail: collatz{at}ccr.jussieu.fr.
Present address: Department of Biosciences, University of Kent,
Canterbury, Kent CT2 7NJ, United Kingdom.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |